Download Free Sample
Buy Now
Market Size
The quantum computing in drug discovery market, valued at USD 315 million in 2025, is projected to reach USD 361 million in 2026 and USD 1,692 million by 2035, representing a CAGR of 18.7% during the forecast period 2026 to 2035.
See What’s in the Full Report – Request Your Complimentary Insights!
Market Report: Key Takeaways
- Driven by the rising demand for on-premise quantum systems, valued for their speed and efficiency, the hardware segment holds a dominant position in quantum computing in drug discovery market.
Your Business is Unique – Why Shouldn’t Your Report Be?
- In terms of drug discovery steps, the lead optimization is likely to secure ~50% of the overall revenue share in 2026, due to its significant role in drug discovery process.
- In terms of target therapeutic area, currently, oncological disorders capture the largest quantum computing in drug discovery market share (~20%). Due to the rising prevalence of cancer and increased demand for potent anticancer drugs, oncology drug discovery services are in high demand.
- In terms of geographical regions, North America captures more than 40% of the market value in the year 2026, due to its strong public and private investments, supportive regulations, and significant funding.
Market Overview
Quantum computing is emerging as a transformative technology in modern drug discovery, enabling researchers to simulate complex molecular interactions with unprecedented precision. This has helped in significantly reducing the time and cost associated with traditional computational methods. By leveraging quantum algorithms and advanced simulation techniques, these systems can analyze chemical spaces that are otherwise intractable for classical computers, which have limited accuracy and require prohibitively long computation times. This integration enhances the efficiency of identifying promising drug candidates, optimizing molecular structures, and predicting biological activity, empowering pharmaceutical companies to develop more effective therapies.
The quantum computing drug discovery sector continues to expand rapidly by leveraging innovations in quantum hardware, software and AI in drug discovery, to improve the accuracy and reduce the timelines of drug discovery. However, the field still faces significant challenges in scaling quantum computing in healthcare applications, including limitations in quantum hardware, error rates, and algorithm stability. Additional hurdles involve selecting appropriate molecular targets, accurately modeling complex biological systems, and integrating quantum workflows with classical computational pipelines.
Achieving cost efficiency and establishing standardized methodologies remain significant hurdles for the widespread adoption of quantum computing in pharma. However, market research reveals that expanding applications in complex disease modeling, molecular simulation, and precision bit are driving momentum in this emerging field. Further, increasing investments in advanced computational technologies and personalized therapeutics further accelerate this growth.
Recent Developments
- In February 2026, XtalPi entered into a collaboration with VISEN Pharmaceuticals to co-develop innovative endocrine therapies by integrating quantum physics, AI, and automated experimentation to explore vast chemical spaces.
- In February 2026, qBraid and Alpine Quantum Technologies (AQT) signed a product / technology integration agreement in order to make high performance quantum computing more accessible to researchers, developers, and innovators around the world.
- In January 2026, Zapata Quantum and University of Maryland announced a research collaboration to demonstrate a fundamentally new approach to building quantum applications grounded in formal verification.
Your Business is Unique – Why Shouldn’t Your Report Be?
Quantum Computing in Drug Discovery Market Trends
- Partnerships and Collaborations: Quantum Computing companies are forming numerous partnerships that are driving market growth. For instance, market players, such as QuEra Computing and IonQ have signed 16 and 14 collaborations, respectively, since 2024 to accelerate the development of quantum computing technologies. Similarly, several other market players are entering into collaborations to integrate technologies and advance research in quantum computing for drug discovery.
- Grants: In recent years, several research organizations have provided financial support to advance research initiatives in the field of quantum computing for drug discovery. Notably, funding agencies have awarded around 40 grants to various organizations for research related to quantum computing in drug discovery, since 2021. For instance, in March 2026, Kvantify secured USD 8.1 million in funding to scale quantum drug discovery platform named Qrunch.
- Growth in Industry Engagement: Quantum computing aided drug discovery has witnessed a surge in number of events, such as conferences, webinars and symposiums. In fact, players are proactively conducting and participating in events to discuss their research findings related to quantum computing in drug discovery. For instance, IBM recently organized a “Quantum Developer Conference” in which quantum computing developers participated from all over the world.
- Growing Emphasis on Logical Qubits: The increasing focus on logical qubit pharma reflects a shift toward building error-corrected quantum systems that can reliably perform complex molecular simulations for drug discovery. This trend aims to overcome hardware limitations by improving stability and scalability, enabling more accurate and commercially viable pharmaceutical research.
- Rising Global Demand for Quantum Computing in Drug Discovery: Quantum computing drives the rising global demand through several benefits, such as increased accuracy, reduced timelines of drug discovery, and potential to simulate complex molecular structures precisely.
Industry Experts on Quantum Computing in Drug Discovery Market
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:
- Chief Executive Officer, Small Organization, US
- Quantum Engineer, Small Organization, US
In addition, the market report includes transcripts of the following other third-party discussions:
- Manager of Quantum Technologies, Large Organization, Finland
- Research Scientist, Very Large Organization, US
Quantum computing in drug discovery domain will mark a turning point in the coming future. Abhay Agarwal, Quantum Engineer, PolarisQB, “Quantum computing is an emerging field, with potential in various domains, such as healthcare, cybersecurity, space science, chemistry and many more. In my opinion, drug discovery and design is one of the key success areas of quantum computing. However, currently the demand for this technology has increased significantly, resulting in unmet needs due to the efficiency perspective”.
Market Drivers
- Enhanced Precision: Ongoing advancements in quantum algorithms, such as error correction techniques, deep learning and hybrid quantum-classical models are improving the accuracy and efficiency of molecular simulations in drug discovery. These innovations enable researchers to model complex biochemical interactions at an unprecedented level of detail, leading to more reliable predictions of drug-target binding and behavior. This precision-driven approach is opening new pathways for identifying novel therapeutics and optimizing drug candidates across a wide range of diseases.
- Next Generation Simulation Capabilities: The emergence of quantum-enhanced simulation tools is redefining the boundaries of molecular research. As investment in quantum technologies increases, scientists can explore complex biochemical systems with greater precision.
- Multi-Modal Quantum Advancements: The development of next-generation hybrid and multi-algorithm quantum computing approaches for drug discovery is poised to significantly accelerate the process by overcoming the limitations of classical computational methods. Leading innovators are exploring integrated frameworks that combine multiple quantum algorithms within a single workflow, enabling the simultaneous optimization of molecular properties, binding affinities, and reaction pathways.
Pay Only for What You Need – The Best Way to Optimize
Market Segmentation Analysis
Oncological Disorders Driving Application of Quantum Computing in Drug Discovery
- According to the market forecast, oncological disorders dominate the current market (~20%). Further, it is worth noting that oncological disorders are likely to grow at a higher CAGR (21.1%), showcasing substantial growth potential during the forecast period.
- This growth is driven by the rising prevalence of cancer, which is increasing demand for anticancer drugs and fueling ongoing research exploration across a broad range of target indications.
Lead Optimization Driving Quantum Computing in Drug Discovery Market Growth
The global market is segmented across different drug discovery steps, such as target identification / validation, hit generation / lead identification, and lead optimization. The lead optimization step captures majority share (~50%) in 2026.
- This growth is driven by the crucial role that lead optimization plays in refining candidate molecules into safe and effective drugs, as well as by the increasing complexity of drug targets and advancements in precision therapies.
Hardware Set to Lead Quantum Computing in Drug Discovery Market
- According to the market forecast by type of offering, the hardware segment dominates the current market (50%).
- A major driver of the quantum computing hardware segment is the advancement and deployment of scalable quantum processors. Companies such as IBM and Google are leveraging qubit technologies, including superconducting circuits and trapped ions, to build these systems.
Market Regional Insights
North America Dominates the Market
In 2035, North America will likely dominate, capturing more than 40% of the market share. Key factors that contribute to the region’s dominance in this industry include robust partnerships between academia and industry players, and the availability of cutting-edge manufacturing capabilities for advanced quantum computing machines. For instance, IonQ, a US based company, has signed an academic agreement with the Korea Institute of Science and Technology Information (KISTI) to support research and development in this domain. Additionally, it is worth highlighting that in November 2025 the US Department of Energy (DOE) has raised USD 625 million in funding to renew its five National Quantum Information Science (QIS) Research Centers.
Quantum Computing in Drug Discovery Adoption in the Asia Pacific Region
The market in Asia-Pacific is likely to observe a higher annualized growth rate of 21.3% during the forecast period. Notable examples of very large companies providing quantum computing based drug discovery, headquartered in Asia-Pacific include Fujitsu, Huawei and Toshiba. The detailed methodology across the global market and revenue generated across various segments is available in the full report.
Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed
Quantum Computing in Drug Discovery Market: Scope of the Report
| Key Report Attributes | Details | |
| Historical Trend | Since 2023 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | USD 361 Million | |
| Market Size 2035 | USD 1,692 Million | |
| CAGR (Till 2035) | 18.7% | |
| Key Players | (A complete list of companies captured is available in the report) | |
| Segments Covered |
|
|
| Excel Data Packs (Complimentary) |
|
|
| PowerPoint Presentation (Complimentary) |
|
|
| Customization Scope |
|
|
Market Segments
Based on the research, we have segmented the Quantum Computing in Drug Discovery Market into type of offering, drug discovery steps, target therapeutic area, end user and geographical regions.
By Type of Offering
- Hardware
- Service
- Platform / Software
By Drug Discovery Steps
- Target Identification / Validation
- Hit Generation / Lead Identification
- Lead Optimization
By Target Therapeutic Area
- Oncological Disorders
- Cardiovascular Disorders
- Musculoskeletal Disorders
- Neurological Disorders
- Respiratory Disorders
- Immunological Disorders
- Gastrointestinal Disorders
- Endocrine Disorders
- Ophthalmological Disorders
- Blood-related Disorders
- Dermatological Disorders
- Infectious Diseases
- Urinary Disorders
By End User
- Pharma and Biotech Companies
- CROs
- Research and Academic Institutions
By Geographical Regions
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Middle East and North Africa
- Saudi Arabia
- UAE
- Egypt
- Latin America
- Brazil
- Mexico
- Argentina
